Abstract
We performed basic studies on a new high-yield culture system (concentrate rotary tissue-culture system) for application to adoptive immunotherapy with lymphokine-activated killer (LAK) cells. Using this system, we demonstrated that up to 2 × 107 peripheral blood mononuclear cells/ml could be cultured in interleukin-2 with a sufficient recovery rate and cytotoxicity in short-term cultures (6 days). This system can also be used to proliferate LAK cells to four times the initial cell number with sufficient cytotoxicity for 14 days of culture. Thus, this system allows activation of sufficient numbers of cells to conduct clinical trials on humans.
Keywords: Clinical Trial, Cancer Research, Culture System, Recovery Rate, Killer Cell
References
- 1.Fisher RI, Coltman CA, Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Int Med. 1988;108:518. doi: 10.7326/0003-4819-108-4-518. [DOI] [PubMed] [Google Scholar]
- 2.Kangas L, Gronroos M, Nieminen AL. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol. 1984;62:338. [PubMed] [Google Scholar]
- 3.Kato K, Yamada T, Kawahara K, Onda H, Asano T, Sugino H, Kakinuma A. Purification and characterization of recombinant human interleukin-2 produced inEscherichia coli . Biochem Biophys Res Commun. 1985;130:692. doi: 10.1016/0006-291x(85)90472-3. [DOI] [PubMed] [Google Scholar]
- 4.McElroy WD, DeLuca MA. The chemistry and applications of firefly luminescence. New York: Academic Press; 1981. Bioluminescence and chemiluminescence. Basic chemistry and analytical applications; p. 179. [Google Scholar]
- 5.Muul LM, Director EP, Hyatt CL, Rosenberg SA. Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods. 1986;88:265. doi: 10.1016/0022-1759(86)90015-3. [DOI] [PubMed] [Google Scholar]
- 6.Nakamura Y, Watanabe K, Noto T, Tajima T, Yamamura M. A new compact and cell dense continuous culture system. J Immunol Methods. 1989;118:31. doi: 10.1016/0022-1759(89)90049-5. [DOI] [PubMed] [Google Scholar]
- 7.Rosenberg SA, Lotze MT, Muul LM, Chang AF, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
- 8.Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987;102:127. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
- 9.West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]